AMRX vs DUK · P/E 44, rev $1.52B vs P/E 19, rev $31.74B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Duke Energy Corporation (DUK) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Duke Energy Corporation (DUK) is a utilities - regulated electric company listed on NYSE.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported DUK revenue for 2025-12-31 was $31.74B. Net income was $4.97B. Revenue was up 5.6% from 2024-12-31 to 2025-12-31. DUK currently screens at market cap $96.46B and trailing P/E 19.0.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. DUK currently screens at market cap $96.46B and trailing P/E 19.0.
Not investment advice. Open the AMRX and DUK stock pages for the full models.
Not investment advice.